Earnings Ahead

CARA - Cara Therapeutics

2.78 0.07 2.58

Cara Therapeutics

Cara Therapeutics

About

Profile

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs).


Headquarters

Stamford, Connecticut, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

CARA



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Cara Therapeutics GAAP EPS of -$0.52 beats by $0.01, revenue of $4.87M misses by $5.08M
  • Cara Therapeutics Q3 2023 Earnings Preview
  • Cara Therapeutics reports up to $40 million non-dilutive financing agreement
  • Cara Therapeutics GAAP EPS of -$0.58 misses by $0.04, revenue of $6.93M beats by $0.23M
  • Cara Therapeutics Q2 2023 Earnings Preview
  • Jefferies says CMS extension for CARA dialysis drug should "unlock stock"
  • UK drug pricing watchdog backs use of Cara, Vifor's Kapruvia in NHS
  • Cara Therapeutics GAAP EPS of -$0.49 beats by $0.03, revenue of $6.17M beats by $1.19M
  • Cara Therapeutics Q1 2023 Earnings Preview
  • Cara, Iovance, and Karyopharm among biotechs with no exposure to SVB (updated)
  • Cara Therapeutics downgraded at BofA on sales forecast for Korsuva
  • Cara Therapeutics plummets 29% on quarterly misses; enough cash to operate to H1 2024
  • Cara Therapeutics GAAP EPS of -$0.56 misses by $0.20, revenue of $3.26M misses by $11.24M
  • Cara Therapeutics GAAP EPS of -$0.43 beats by $0.01, revenue of $10.81M beats by $1.95M
  • Cara Therapeutics Q3 2022 Earnings Preview
  • SWK Holdings unit receives $5M payment from Cara Therapeutics
  • Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients
  • Cara Therapeutics hires new finance chief
  • Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients
  • Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M

Earnings History

Date EPS / Forecast Revenue / Forecast
November 8, 2021 -0.02 / -0.3863 20.27M / 15.59M Beat!
August 9, 2021 -0.61 / -0.5483 - / -
May 10, 2021 -0.47 / -0.5733 1.94M / 3.03M
February 25, 2021 1.59 / 0.3643 112.09M / 5.98M Beat!
November 9, 2020 -0.35 / -0.5971 9.27M / 4.73M Beat!
August 10, 2020 -0.54 / -0.67 5.63M / 5.01M Beat!
May 11, 2020 -0.62 / -0.6 8.09M / 4.71M Beat!
February 27, 2020 -0.61 / -0.66 4.51M / 5.39M
November 5, 2019 -0.74 / -0.58 5.79M / 4.84M Beat!
August 7, 2019 -0.58 / -0.61 5.21M / 3.06M Beat!
May 7, 2019 -0.56 / -0.58 4.38M / 3.29M Beat!
March 12, 2019 -0.52 / -0.58 5.53M / 2.67M Beat!
November 6, 2018 -0.51 / -0.49 5.06M / 3.4M Beat!
August 7, 2018 -0.52 / -0.51 2.87M / 150K
May 9, 2018 -0.51 / -0.47 188K / 62.67K Beat!
March 15, 2018 -0.43 / -0.40 2.87M / 0.02M Beat!
November 2, 2017 -0.38 / -0.34 2.87M / 0.19M Beat!
August 3, 2017 -0.29 / -0.62 2.87M / 0.02M Beat!
May 4, 2017 -0.81 / -0.62 911.0K / - Beat!
Date Price Open High Low Vol Change ER
Oct 9, 2023 1.44 1.47
1.48
1.36
455K -2.7%
Oct 6, 2023 1.48 1.48
1.5
1.4
369K 0%
Oct 5, 2023 1.48 1.42
1.5
1.41
431K 2.78%
Oct 4, 2023 1.44 1.58
1.59
1.4
786K -11.11%
Oct 3, 2023 1.62 1.64
1.65
1.58
474K -1.22%
 
Oct 2, 2023 1.64 1.66
1.67
1.61
383K -2.38%
Sep 29, 2023 1.68 1.69
1.74
1.67
419K -0.59%
Sep 28, 2023 1.69 1.69
1.7
1.59
464K 0.60%
Sep 27, 2023 1.68 1.79
1.86
1.64
728K -6.15%
Sep 26, 2023 1.79 1.68
1.87
1.68
540K 4.68%
Sep 25, 2023 1.71 1.7
1.77
1.61
920K 2.40%
Sep 22, 2023 1.67 1.72
1.73
1.66
562K -2.91%
Sep 21, 2023 1.72 1.76
1.8
1.71
533K -3.91%
Sep 20, 2023 1.79 1.92
1.92
1.73
531K -7.73%
Sep 19, 2023 1.94 1.88
1.98
1.85
408K 3.19%
Sep 18, 2023 1.88 2.3
2.31
1.88
1.3M -19.66%
Sep 15, 2023 2.34 2.07
2.48
2.06
2.9M 13.04%
Sep 14, 2023 2.07 1.87
2.09
1.84
1.4M 13.74%
Sep 13, 2023 1.82 1.72
1.89
1.7
1.1M 5.81%
Sep 12, 2023 1.72 1.83
1.83
1.71
1.1M -6.01%
Sep 11, 2023 1.83 1.92
1.97
1.82
662K -4.69%
Sep 8, 2023 1.92 2
2
1.88
795K -3.03%
Sep 7, 2023 1.98 2.13
2.14
1.94
1.1M -8.33%
Sep 6, 2023 2.16 2.16
2.25
2.12
806K 0%
Sep 5, 2023 2.16 2.42
2.46
2.11
1.5M -10%
Sep 1, 2023 2.4 2.6
2.66
2.36
1.6M -6.61%
Aug 31, 2023 2.57 2.73
2.78
2.56
621K -5.86%
Aug 30, 2023 2.73 2.79
2.85
2.72
228K -2.85%
Aug 29, 2023 2.81 2.8
2.87
2.78
273K 0%
Aug 28, 2023 2.81 2.78
2.86
2.78
319K 1.08%
Aug 25, 2023 2.78 2.87
2.88
2.71
311K -2.46%
Aug 24, 2023 2.85 3.03
3.03
2.85
456K -5.32%
Aug 23, 2023 3.01 2.96
3.04
2.96
301K 1.35%
Aug 22, 2023 2.97 3.03
3.04
2.95
391K -1.66%
Aug 21, 2023 3.02 2.98
3.06
2.95
427K 1.34%
Aug 18, 2023 2.98 2.95
3.04
2.9
530K -1%
Aug 17, 2023 3.01 2.95
3.06
2.91
583K 2.73%
Aug 16, 2023 2.93 3
3.02
2.92
504K -2.33%
Aug 15, 2023 3 3
3.03
2.96
549K 0%
Aug 14, 2023 3 3.06
3.06
2.95
476K -2.28%
Aug 11, 2023 3.07 3.06
3.09
2.99
318K -0.65%
Aug 10, 2023 3.09 3.04
3.27
2.98
474K 2.32%
Aug 9, 2023 3.02 2.91
3.04
2.84
612K 2.72%
Aug 8, 2023 2.94 2.93
3.08
2.84
1.7M -0.34%
Aug 7, 2023 2.95 3.1
3.1
2.91
605K -5.75%
Aug 4, 2023 3.13 3.2
3.26
3.12
311K -1.88%
Aug 3, 2023 3.19 3.07
3.24
3.05
523K 3.24%
Aug 2, 2023 3.09 3.16
3.16
3
397K -1.59%
Aug 1, 2023 3.14 3.31
3.34
3.09
1.1M -5.71%
Jul 31, 2023 3.33 3.28
3.45
3.26
1.2M 1.83%
Jul 28, 2023 3.27 3.15
3.29
3.14
714K 6.17%
Jul 27, 2023 3.08 2.95
3.17
2.95
1.1M 4.76%
Jul 26, 2023 2.94 2.79
2.94
2.77
608K 5.38%
Jul 25, 2023 2.79 2.88
2.92
2.78
567K -3.46%
Jul 24, 2023 2.89 2.93
3.03
2.86
383K -2.03%
Jul 21, 2023 2.95 2.94
3.02
2.9
440K 1.03%
Jul 20, 2023 2.92 3.1
3.12
2.83
722K -6.11%
Jul 19, 2023 3.11 3.06
3.18
3.02
804K 1.63%
Jul 18, 2023 3.06 2.86
3.13
2.86
927K 6.62%
Jul 17, 2023 2.87 2.84
3.01
2.82
768K 0%